Close Menu

NEW YORK – OpGen announced on Wednesday a preliminary 19 percent revenue increase for 2019 to $3.5 million from $3 million in 2018.

Revenue from the company's Acuitas AMR Gene Panel and Acuitas Lighthouse increased 147 percent to approximately $1.4 million, and preliminary operating loss was approximately $12.4 million, down 7 percent from $13.4 million in 2018. OpGen said it will announce its full-year and fourth quarter financial results in March.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.